8-K: Predictive Oncology Q3 2025: Digital Asset Shift & Losses

Predictive Oncology reported significant Q3 2025 losses driven by a derivative liability from its new digital asset strategy focused on Aethir's ATH token.

Summary

• Reported a net loss of $(77,651,843) for the third quarter ended September 30, 2025, compared to $(3,094,690) for the same period in 2024.
• Basic and diluted loss per common share from continuing operations was $(107.25) for Q3 2025, significantly higher than $(7.26) for Q3 2024.
• The Q3 2025 net loss included a $74.4 million derivative liability related to the initiation of its digital asset treasury strategy focused on the ATH token.
• Initiated a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, expanding its business to include active digital asset management.
• Received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million from two private placements.
• As of November 10, 2025, held approximately 5.70 billion ATH tokens, with a market value of approximately $152.8 million (based on $0.0268 per ATH), of which 3.7 billion are locked/restricted and 2.0 billion are unlocked.
• Announced a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing into new indications.
• Cash and cash equivalents from continuing operations were $181,667 as of September 30, 2025, a decrease from $611,822 as of December 31, 2024.
• Stockholders deficit increased to $77.4 million as of September 30, 2025, from $202,610 as of December 31, 2024.
• Revenue for Q3 2025 was $3,618, largely unchanged from $3,907 in Q3 2024.
• General and administrative expenses increased by $1.1 million to $2.6 million in Q3 2025, primarily due to increased legal fees and stock-based compensation.

Sentiment

Score: 3

Explanation: While the company has initiated a potentially transformative digital asset strategy and raised significant capital (both cash and digital assets), the immediate financial results show a substantial net loss and increased deficit, primarily due to a large derivative liability. This indicates high risk and uncertainty associated with the new strategy, despite its potential long-term upside.

Positives

• Successfully raised approximately $50.8 million in cash gross proceeds through private placements.
• Secured in-kind contributions of ATH tokens with a notional value of approximately $292.7 million, establishing a significant digital asset reserve.
• Expanded business strategy to include active digital asset management and monetization of AI infrastructure, potentially diversifying revenue streams.
• Appointed Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, to its Board of Directors, bringing significant financial expertise.
• Formed a strategic collaboration with Every Cure to advance drug repurposing efforts.
• Net cash used in operating activities of continuing operations decreased to $5.9 million for the nine months ended September 30, 2025, from $8.0 million in the comparable prior period.

Negatives

• Reported a substantial net loss of $(77.65) million in Q3 2025, a significant increase from $(3.09) million in Q3 2024.
• Basic and diluted loss per common share worsened dramatically to $(107.25) in Q3 2025.
• Recorded a $74.4 million derivative liability related to the digital asset strategy, contributing heavily to the net loss.
• Cash and cash equivalents from continuing operations decreased to $181,667 as of September 30, 2025.
• Stockholders deficit increased significantly to $77.4 million as of September 30, 2025.
• Revenue remained very low and largely flat at $3,618 in Q3 2025.
• General and administrative expenses increased by $1.1 million due to higher legal fees and stock-based compensation.

Risks

• Failing to realize the anticipated benefits of the digital asset treasury strategy.
• Economic conditions and their impact on the company's operations and digital asset values.
• Fluctuations in the market price of ATH and other digital assets, which can significantly impact asset valuation and financial results.
• The evolving regulatory environment for digital assets and its potential impact on the company's business model.
• The ability to successfully execute the digital asset treasury strategy and its implications for shareholders and the core drug discovery business.
• The ability of the Aethir ecosystem to perform in a manner consistent with projections and support the company's operational goals.
• The requirement for shareholder approval for the exercise of pre-funded warrants issued in connection with the private placement.
• Risks related to the success of collaboration arrangements, commercialization activities, and product sales levels by collaboration partners.

Future Outlook

The company is expanding its business to include active digital asset management, aiming to monetize AI infrastructure through real enterprise deployments intended to generate booked revenue and cash earnings. This strategy involves using ATH on the Aethir network to meet global AI infrastructure demand, addressing what management views as a key bottleneck limiting breakthrough innovation.

Management Comments

• Raymond Vennare, Chairman and CEO: "We recognize a key inhibitor to AI innovation across sectors is the availability of high performance, affordable AI infrastructure. Aethir operates the worlds largest decentralized GPU network, offering enterprise-grade AI at a significantly lower cost as compared to other providers. We view expanded access to affordable and reliable AI infrastructure as key to eliminating the bottleneck that we believe is limiting breakthrough innovation. To that end, we are excited that Predictive Oncology is able deploy a new business line in active digital asset management, allowing us to play a role in the democratization of AI broadly while also addressing the growing need for advanced computing power."
• Kyle Okamoto, Aethir General Manager & CTO and Predictive Oncology advisory board member: "Aethir is thrilled to partner with Predictive Oncology to drive the future of decentralized AI infrastructure. By providing the infrastructure backbone for Predictive Oncologys new digital asset strategy, Aethir is unlocking greater value for its ecosystem, further democratizing AI access, and empowering enterprises with flexible, scalable, and cost-effective compute solutions. I am excited for what we'll achieve through this mutually beneficial synergy. Predictive Oncology's new digital asset strategy will be a use case of how the AI ecosystem actually grows: not through passive capital, but through operators who acquire compute infrastructure, deploy it to real enterprises, and monetize it transparently. That's a model aimed to scaleand it's exactly why Aethir and Predictive Oncology are so excited about this synergy."

Industry Context

The announcement positions Predictive Oncology at the intersection of AI drug discovery and the rapidly growing decentralized AI infrastructure market. The strategic pivot into digital asset management with Aethir addresses the global demand for high-performance, affordable AI compute, which is a significant bottleneck for AI innovation across various sectors. This strategy aims to leverage the growth in both artificial intelligence and blockchain technologies to create a new business line.

Management Changes

Stakeholder Impact

• Shareholders face potential for significant volatility due to the new digital asset strategy and its associated risks (e.g., ATH price fluctuations, evolving regulatory environment). There is also a potential for long-term upside if the strategy is successful, but immediate negative impact from the large net loss and increased deficit.
• Employees may experience changes in compensation structure, with increased stock-based compensation for employees, directors, and consultants, alongside decreased employee salaries and benefits resulting from lower headcount in some areas.
• Customers and partners could benefit from the strategic collaboration with Every Cure for drug repurposing and the potential for more affordable AI infrastructure through the Aethir partnership.

Next Steps

• Host an investor conference call and webcast on Monday, November 17th, at 9:00 am EST to review Q3 results and the new digital asset treasury strategy.
• Develop systems to monetize AI infrastructure through real enterprise deployments intended to generate booked revenue and cash earnings.
• Seek shareholder approval for the exercise of pre-funded warrants issued in connection with the private placement.

Key Dates

Recommendation

The company is undergoing a significant strategic pivot into digital assets and AI infrastructure, which carries both high potential reward and substantial risk. While the capital raise and the vision for monetizing AI infrastructure are positive, the immediate financial results show a massive net loss driven by a derivative liability, and the core drug discovery revenue remains minimal. The future success hinges heavily on the volatile digital asset market and the execution of an unproven business model. A 'Hold' recommendation reflects the uncertainty and the need to observe how the new strategy unfolds and impacts future financial performance, rather than making a definitive 'Buy' or 'Sell' decision at this early, high-risk stage.

Keywords

Predictive Oncology, POAI, Aethir, ATH token, digital asset strategy, AI drug discovery, decentralized GPU, Q3 2025 financial results, earnings report, biotechnology, artificial intelligence, crypto, blockchain, drug repurposing, corporate governance